A Randomized Phase Ii Multi-Institutional Trial Of Anlotinib Plus Docetaxel Versus Docetaxel In Egfr-Wild-Type Non-Small Cell Lung Cancer (Nsclc) Patients After Progression On First-Line Platinum-Base Chemotherapy: Alter-L018.
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要